BioDelivery Sciences International to Host ELYXYB™ Investor Day
The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults...
News
Arch Therapeutics Announces Appointment of Larry Hicks to the Board
Brings deep industry experience to support commercialization planFRAMINGHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH)...
Adaptive Biotechnologies Launches Enhanced clonoSEQ® Assay Reports for Patients with Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status
Combined ID-IGHV report at time of diagnosis conveniently provides additional prognostic information while also enabling future MRD monitoring in patientsSEATTLE,...
OpGen Initiates Clinical Trial for Unyvero Urinary Tract Infection Panel
OpGen’s Unyvero Urinary Tract Infection (UTI) Panel tests for a broad range of pathogens as well as antimicrobial resistance markers...
Holderness School Deploys Augmented Radar Imaging’s WellnessDetector™ For COVID-19 Screening
Free-Standing Devices Rapidly Test Approximately 400 Individuals Up To Three Times Per DayLOS ALTOS, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE)...
Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Company Invited to Deliver Oral Presentation in “Drugging Difficult Targets” Plenary SessionREDWOOD CITY, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) --...
Eve & Co Incorporated Announces Director and Management Changes
STRATHROY, Ontario, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V: EVE;...
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa
VANCOUVER, British Columbia, Sept. 30, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader...
TG Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the submission of a Biologics License...
LifeMD Announces Pricing of Public Offering 1,400,000 Shares of 8.875% Series A Cumulative Perpetual Preferred Stock
NEW YORK, Sept. 30, 2021 (GLOBE NEWSWIRE) -- LifeMD, Inc. (“the Company”) (NASDAQ: LFMD), a rapidly growing direct-to-patient telehealth company today...
Starton Therapeutics Announces Successful Results in STAR-LLD Toxicology Study: No Myelosuppression and Excellent Tolerability
Study marks completion of IND-enabling work for STAR-LLD in multiple myeloma and chronic lymphocytic leukemia (CLL)PARAMUS, N.J., Sept. 30, 2021...
Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial
MENLO PARK, Calif., FOSTER CITY, Calif. and HANGZHOU, China, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Edison Oncology Holding Corp. (“Edison...
uniQure to Participate in Multiple Upcoming Industry Conferences in October
LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing...
Genenta Strengthens Senior Management With Key Strategic Appointments
Gaurav Shah, Brad Loncar and Alec Ross appointed as strategic advisorsBarbara Regonini joins recently hired CFO, Richard Slansky, completing senior...
Non-Executive Director Appointment
Synairgen plc(‘Synairgen’ or the ‘Company’) Non-Executive Director Appointment Southampton, UK – 30 September 2021: Synairgen plc (LSE: SNG), the drug...
Interim results for the six months ended 30 June 2021
Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2021 Scaling up and preparing for...
Nurix Therapeutics Expands its Board of Directors with the Addition of Two Industry Leaders
SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation...
Trevena Announces Results of TRV027 Proof-of-Concept Study in COVID-19 Patients
-- 92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with...
Christina Lake Cannabis Optimizes Harvesting and Trimming Techniques for 2021 Crop
Picture 1 Christina Lake Cannabis team members are pictured above preparing freshly harvested cannabis plants for further processing and refinement....
AIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses
The governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in...
